Martorell et al. reported that VDR, a TF associated with anti-inflammation and anti-proliferation, interacts with RXRα and inhibits the activation of MAPK pathway, VEGF expression, and ECM degradation in VECs, exhibiting anti-inflammatory and anti-neovascularization effects, thereby inhibiting AAA progression (84). The gene discussed is TF; the disease is triple-A syndrome.